State of Alaska Epidemiology





Department of Health and Social Services Karleen Jackson, Commissioner

3601 C Street, Suite 540, PO Box 240249 Anchorage, AK 99524-0249 <u>http://www.epi.Alaska.gov</u> **Division of Public Health** Jay C. Butler, MD, Director Local (907) 269-8000 24 Hour Emergency 1-800-478-0084 Editors: Bradford D. Gessner, MD, MPH Joe McLaughlin, MD, MPH Bulletin No. 14 April 23, 2007

Recommended Immunization Schedule for Children Aged 0–6 Years — Alaska, 2007

Age ► Vaccine ▼	Birth	2 mos	4 mos	6 mos	12 mos	15 mos	18 mos	19–23 mos	2–3 yrs	4–6 yrs
Hepatitis B	Hep B	Pediarix [®]	Pediarix®	Pediarix [®]			Н		ep B series	
Diphtheria, Tetanus, Pertussis (DTaP)		or Hep B DTaP	or DTaP	<i>or</i> Hep B DTaP		DT	ſaP			DTaP
Polio (IPV)		IPV	IPV	IPV						IPV
Rotavirus		Rota	Rota	Rota						
Hib		Hib	Hib		Н	ib	Hib			
Pneumococcal		PCV	PCV	PCV	PCV			PCV PPV		
Influenza					Influenza (yearly)					
Measles, Mumps, Rubella (MMR)					MMR					MMR
Varicella					Varicella					Varicella
Hepatitis A					Hep A (2 doses)				Hep A series	
Meningococcal								MPSV4		

Catch-up immunization

Hepatitis B (Hep B) (minimum age: birth)

- At birth:
- Administer monovalent Hep B to all newborns prior to hospital discharge.
- If mother is HBsAg+, administer Hep B and 0.5 mL of Hep B immune globulin (HBIG) within 12 hrs of birth.
- If mother's HBsAg status is unknown, administer Hep B within 12 hrs of birth. Determine HBsAg status as soon as possible and, if HBsAg+, administer HBIG (no later than age 1 wk).
- If mother is HBsAg-, birth dose can only be delayed with a physician's order and mother's negative HBsAg laboratory report documented in the infant's medical record.

Following the birth dose:

Complete series with either monovalent Hep B or *Pediarix*[®]. Dose 2 should be administered at age 1–2 mos, at least 4 wks after dose 1. The final dose should be administered at age ≥24 wks. Infants born to HBsAg+ mothers should be tested for HBsAg and antibody to HBsAg after completion of ≥3 doses of a licensed Hep B series, at age 9–18 mos (generally at the next well-child visit).

4-month dose of Hep B:

• It is permissible to administer 4 doses of Hep B when *Pediarix*[®] is used after the birth dose. If monovalent Hep B is used for doses recommended after the birth dose, a dose at age 4 mos is not needed.

Rotavirus vaccine (Rota) (minimum age: 6 wks)

- Administer dose 1 at age 6–12 wks. Do not begin series if child is aged \geq 13 wks.
- Administer final dose in series by age 32 wks. Do not continue series if child is aged \geq 33 wks.

Diphtheria & tetanus toxoids & acellular pertussis vaccine (DTaP) (minimum age: 6 wks)

- Dose 4 may be administered as early as age 12 mos, provided 6 mos have elapsed since dose 3.
- Administer final dose in series at age 4–6 yrs.

Haemophilus influenzae type b conjugate vaccine (Hib) (minimum age: 6 wks)

- Three doses of PedvaxHIB[®] constitute a complete series.
- Dose 3 should not be given prior to age 12 mos.
- Children receiving dose 1 at age ≥7 mos require fewer doses to complete series.

<u>http://www.cdc.gov/mmwr/preview/mmwrhtml/00041736.htm</u> (Table 4) • Hib vaccine generally not recommended for children aged ≥5 yrs.

Pneumococcal vaccine (minimum age: 6 wks for pneumococcal conjugate vaccine [PCV]; 2 yrs for pneumococcal polysaccharide vaccine [PPV])

• Four doses of PCV for all Alaska children aged 6 wks to 23 mos.

Certain high-risk groups

- Children receiving dose 2 at age ≥7 mos require fewer doses to complete series. <u>http://www.cdc.gov/mmwr/PDF/rr/rr4909.pdf</u> (Table 11)
- One dose of PCV may be given to any incompletely immunized child aged 24–59 mos. PPV is approved for persons aged ≥2 yrs with certain underlying medical conditions (e.g., sickle cell disease or HIV). http://www.cdc.gov/mmwr/PDF/rr/rr4909.pdf (Table 12)

Influenza vaccine (minimum age: 6 mos for trivalent inactivated influenza vaccine [TIV]; 5 yrs for live, attenuated influenza vaccine [LAIV])

- All children aged 6–59 mos and close contacts of all children aged 0–59 mos are recommended to receive influenza vaccine.
- Influenza vaccine is recommended annually for children aged ≥ 60 mos with certain risk factors, health care workers, and other persons (including household contacts) in close contact with groups at high risk.
- For healthy persons aged 5–49 yrs, LAIV may be used as an alternative to TIV.
- Children receiving TIV should receive 0.25 mL if aged 6–35 mos or 0.5 mL if aged \geq 3 yrs.
- Children aged <9 yrs who are receiving influenza vaccine for the 1^{st} time should receive 2 doses (separated by ≥ 4 weeks for TIV and ≥ 6 wks for LAIV). (*New recommendation to be issued for 07/08 season.*)

Measles, mumps and rubella vaccine (MMR)

(minimum age: 12 mos)

• Administer dose 2 of MMR at age 4–6 yrs. May be administered before age 4–6 yrs, provided ≥4 weeks have elapsed since dose 1 and both doses are administered at age ≥12 mos.

Varicella vaccine (minimum age: 12 mos)

Administer dose 2 of varicella vaccine at age 4–6 yrs. May be administered before age 4–6 yrs, provided that ≥3 mos have elapsed since dose 1 and both doses are administered at age ≥12 mos. If dose 2 was administered ≥28 days following dose 1, the 2nd dose does not need to be repeated.

Hepatitis A vaccine (Hep A) (minimum age: 12 mos)

- Recommended for all children aged 1 year (i.e., aged 12–23 mos).
- The two doses in series should be administered at least 6 mos apart.
- Children not fully vaccinated by age 2 yrs may be vaccinated at subsequent visits.

Meningococcal polysaccharide vaccine (MPSV4)

(minimum age: 2 yrs)

• Administer MPSV4 to children aged 2–10 yrs with terminal complement deficiencies or functional asplenia and certain other high risk groups. <u>http://www.cdc.gov/mmwr/PDF/rr/rr5407.pdf</u> (Table 6)